The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
1) Histologically confirmed acute myeloid leukemia (non-M3). Treatment-na?ve and unable to receive standard cytarabine and anthracycline induction regimens due to age or comorbidities or patient preference.
1)Acute promyelocytic leukemia (APL) and low risk cytogenetics such as t(8;21), inv(16) or t(16;16).
The First Affiliated Hospital of Xiamen University
Lead sponsor
Chipscreen Biosciences, Ltd.
Collaborator
CSPC Pharmaceutical Group Limited
Collaborator
Fujian Provincial Hospital
Collaborator
Fujian Cancer Hospital
Collaborator
Zhangzhou manicipal hospital of Fujian Province
Collaborator
Jieyang People's Hospital
Collaborator
Huizhou Municipal Central Hospital
Collaborator